Opportunities Preloader

Please Wait.....

Report

Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032

Market Report I 2023-10-01 I 140 Pages I EMR Inc.

Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032
Global Pulmonary Drug Delivery Systems Market Outlook
The global pulmonary drug delivery systems market size was valued at USD 56.9 billion in 2023, driven by both technological advancements and changing healthcare needs across the globe. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 93.3 billion by 2032.

Pulmonary Drug Delivery Systems: Introduction

Pulmonary drug delivery systems refer to methodologies and devices that administer medications directly into the lungs. The primary advantage of this mode of delivery is that it offers a direct route to the respiratory system, allowing for rapid and efficient absorption of drugs, especially those intended for local action within the lungs. Given the vast surface area and highly vascularized nature of the lungs, they serve as an excellent site for the absorption of therapeutics.

Key Trends in the Global Pulmonary Drug Delivery Systems Market
The global pulmonary drug delivery systems market is undergoing transformative changes, driven by both technological advancements, and changing healthcare needs. A significant trend is the development of smart inhalers, equipped with sensors and connectivity features, allowing for better dose tracking, patient adherence, and data collection for personalized treatment. With the rising prevalence of respiratory diseases, especially in urban areas due to pollution and changing lifestyles, there's a heightened demand for advanced and efficient inhalation devices.
Another notable shift is the exploration of the pulmonary route for the delivery of non-respiratory drugs, expanding the potential applications of these systems. The industry is also witnessing a surge in collaborations between pharmaceutical and tech companies, aiming to integrate digital technology into drug delivery for enhanced patient outcomes.
Moreover, with the global focus on reducing the invasiveness of treatments, pulmonary systems offer a promising non-invasive alternative, driving further interest and investment. In essence, the global pulmonary drug delivery systems market is on a trajectory marked by technological integration, expanded therapeutic applications, and a patient-centric approach, promising improved healthcare outcomes in the respiratory domain and beyond.
Global Pulmonary Drug Delivery Systems Market Segmentation

Market Breakup by Product Type
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
o Jet Nebulizers
o Soft Mist Nebulizers
o Ultrasonic Nebulizers
- Others

Market Breakup by Applications
- Cystic Fibrosis
- Asthma
- Allergic Rhinitis
- COPD
- Others

Market Breakup by End User
- Hospitals
- Diagnostic Centres
- Homecare Settings
- Others

Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa


Global Pulmonary Drug Delivery Systems Market Overview
The global pulmonary drug delivery systems market is experiencing a robust expansion, primarily driven by the escalating incidence of respiratory disorders such as asthma and COPD. As the need for effective and rapid treatment modalities grows, so does the demand for advanced inhalation devices like metered-dose inhalers, dry powder inhalers, and nebulizers. Modern technological integrations, including smart inhalers with digital adherence tracking features, are setting new standards in the industry. Beyond treating respiratory ailments, the potential of the pulmonary route for systemic drug delivery is being increasingly recognized, broadening the market's scope. Emerging markets, with their growing healthcare infrastructures and increasing awareness, are contributing significantly to the market's growth.
Furthermore, strategic collaborations between tech firms and pharmaceutical giants are fostering innovations that promise enhanced patient experiences and outcomes. Collectively, with its technological advancements, diverse therapeutic applications, and a focus on patient convenience, the global pulmonary drug delivery systems market is poised for sustained growth and evolution.
Global Pulmonary Drug Delivery Systems Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Koninklijke Philips NV
- GlaxoSmithKline PLC
- 3M
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Cipla Inc.
- Merck & Co.
- GF Health Products Inc.
- Aerogen
- PARI GmbH
- Gilbert Technologies

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Pulmonary Drug Delivery Systems Market Overview
3.1 Global Pulmonary Drug Delivery Systems Market Historical Value (2017-2023)
3.2 Global Pulmonary Drug Delivery Systems Market Forecast Value (2024-2032)
4 Global Pulmonary Drug Delivery Systems Market Landscape
4.1 Global Pulmonary Drug Delivery Systems Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Pulmonary Drug Delivery Systems Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Global Pulmonary Drug Delivery Systems Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Pulmonary Drug Delivery Systems Market Segmentation
6.1 Global Pulmonary Drug Delivery Systems Market by Product Type
6.1.1 Market Overview
6.1.2 Dry Powder Inhalers
6.1.3 Metered Dose Inhalers
6.1.4 Nebulizers
6.1.4.1 Jet Nebulizers
6.1.4.2 Soft Mist Nebulizers
6.1.4.3 Ultrasonic Nebulizers
6.1.5 Others
6.2 Global Pulmonary Drug Delivery Systems Market by Applications
6.2.1 Market Overview
6.2.2 Cystic Fibrosis
6.2.3 Asthma
6.2.4 Allergic Rhinitis
6.2.5 COPD
6.2.6 Others
6.3 Global Pulmonary Drug Delivery Systems Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centres
6.3.4 Homecare Settings
6.3.5 Others
6.4 Global Pulmonary Drug Delivery Systems Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Pulmonary Drug Delivery Systems Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Pulmonary Drug Delivery Systems Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Pulmonary Drug Delivery Systems Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Pulmonary Drug Delivery Systems Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Pulmonary Drug Delivery Systems Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Koninklijke Philips NV
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 GlaxoSmithKline PLC
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 3M
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Novartis AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Boehringer Ingelheim International GmbH
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 AstraZeneca
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Cipla Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Merck & Co.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 GF Health Products Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Aerogen
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 PARI GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Gilbert Technologies
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
18 Global Pulmonary Drug Delivery Systems Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE